Indication Prioritization and Commercial Assessment

Summary

SciVida assisted a biotech company in assessing the market opportunity and prioritizing multiple indications for a promising franchise of early-stage assets to inform key strategic commercial and clinical development decisions.

Situation

Believing opportunity existed in a number of potential indications for their early-stage assets, our client asked SciVida for assistance in conducting a deep-dive assessment of opportunity across indications to determine and prioritize the most attractive indications for commercialization and the requirements for success in each, particularly regarding the clinical profile and endpoints.

SciVida’s Approach

After compiling existing market insights and assumptions and identifying critical gaps, our team went about building the fact base for our client through a combination of desk research, third-party data analysis, and primary research.

Armed with the competitive landscape and market size details from our secondary research and data analysis, we then conducted primary research with physician specialists, key opinion leaders (KOLs), and pharmacy and medical directors at key payer accounts to elucidate the market landscape, target product profile attributes and points of differentiation, guidance on pricing boundaries and access considerations, and positioning and strategic options for the assets.

Leveraging the output from the research efforts, we characterized details related to the opportunities, attractiveness, and requirements for success of the multiple indications being considered. Our team defined and mapped out strategic options for the assets within and across key market segments, i.e., the realm of possibilities, and then conducted working sessions with the client to review the options and identify and align on key criteria against which to evaluate them. 

Using the agreed-upon criteria, team input, fact base, and clinical research to date on the assets, we objectively evaluated the options and tradeoffs. SciVida then leveraged all findings into a comprehensive assessment and prioritization of the opportunity in several indications to guide clinical development and commercialization strategy for the products.